Xu He N, Tchou Julia, Feng Min, Zhao Huaqing, Li Lin Z
University of Pennsylvania, Perelman School of Medicine, Department of Radiology, Molecular Imaging Laboratory, B6 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104, United StatesbUniversity of Pennsylvania, Perelman School of Medicine, Department of Biochemistry and Biophysics, Johnson Research Foundation, Britton Chance Laboratory of Redox Imaging, R171 John Morgan Building, 3620 Hamilton Walk, Philadelphia, Pennsylvania 19104, United States.
University of Pennsylvania, Perelman School of Medicine, Division of Endocrine and Oncologic Surgery, Department of Surgery, West Pavilion 3rd Floor, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, United StatesdUniversity of Pennsylvania, Perelman School of Medicine, Abramson Cancer Center, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, United StateseUniversity of Pennsylvania, Perelman School of Medicine, Rena Rowan Breast Center, West Pavilion, 3rd Floor, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, United States.
J Biomed Opt. 2016 Nov 1;21(11):114003. doi: 10.1117/1.JBO.21.11.114003.
Our long-term goal was to investigate the potential of incorporating redox imaging technique as a breast cancer (BC) diagnosis component to increase the positive predictive value of suspicious imaging finding and to reduce unnecessary biopsies and overdiagnosis. We previously found that precancer and cancer tissues in animal models displayed abnormal mitochondrial redox state. We also revealed abnormal mitochondrial redox state in cancerous specimens from three BC patients. Here, we extend our study to include biopsies of 16 patients. Tissue aliquots were collected from both apparently normal and cancerous tissues from the affected cancer-bearing breasts shortly after surgical resection. All specimens were snap-frozen and scanned with the Chance redox scanner, i.e., the three-dimensional cryogenic NADH/Fp (reduced nicotinamide adenine dinucleotide/oxidized flavoproteins) fluorescence imager. We found both Fp and NADH in the cancerous tissues roughly tripled that in the normal tissues ( p < 0.05 ). The redox ratio Fp/(NADH + Fp) was ? 27 % higher in the cancerous tissues ( p < 0.05 ). Additionally, Fp, or NADH, or the redox ratio alone could predict cancer with reasonable sensitivity and specificity. Our findings suggest that the optical redox imaging technique can provide parameters independent of clinical factors for discriminating cancer from noncancer breast tissues in human patients.
我们的长期目标是研究将氧化还原成像技术作为乳腺癌(BC)诊断组成部分的潜力,以提高可疑成像结果的阳性预测值,并减少不必要的活检和过度诊断。我们之前发现动物模型中的癌前组织和癌组织显示出线粒体氧化还原状态异常。我们还揭示了三名BC患者癌组织标本中线粒体氧化还原状态异常。在此,我们将研究扩展至纳入16名患者的活检样本。在手术切除后不久,从受影响的患侧乳房的看似正常的组织和癌组织中均采集组织样本。所有标本均速冻,并使用Chance氧化还原扫描仪进行扫描,即三维低温NADH/Fp(还原型烟酰胺腺嘌呤二核苷酸/氧化型黄素蛋白)荧光成像仪。我们发现癌组织中的Fp和NADH含量大约是正常组织中的三倍(p < 0.05)。癌组织中的氧化还原比率Fp/(NADH + Fp)高出约27%(p < 0.05)。此外,单独的Fp、NADH或氧化还原比率能够以合理的敏感性和特异性预测癌症。我们的研究结果表明,光学氧化还原成像技术能够提供独立于临床因素的参数,用于区分人类患者的癌性和非癌性乳腺组织。